Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-01 +/- Nivolumab in Advanced Solid Tumors
NCT05122572Phase 1Unknown
- Sponsor
- Wuxi People's Hospital
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RT-01 in solid tumor (advanced stage), sponsored by Wuxi People's Hospital. Primary endpoint: Dose Limiting Toxicities at 28 days. Status: unknown.
02
Drugs
RT-01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05122572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122572.